The NYSCF Conference 2020

HUB Organoids™: Patient-Derived Organoids for Drug Development and Patient Stratification

Key to the development of the HUB Organoid Technology was the discovery of LGR5+ intestinal adult stem cells by the Clevers’ lab. With the identification of these stem cells, we were able to develop a culture system that allowed for the virtually unlimited, genetically and phenotypically stable expansion of the epithelial cells from animals including humans, both from healthy and diseased tissue (Sato et al., Nature 2009, 2011; Gastroenterology 2011; Huch et al., Nature 2013, Cell 2015; Boj et al., Cell 2015).

Since the initial development, we have generated HUB organoid models of different tissue origin like colon, lung, breast, pancreas and ovary for the study of Cancer, Cystic Fibrosis and other diseases (Dekkers, Nat Med 2013; van de Wetering, Cell 2015; Drost et al Nature 2015). These organoids have been characterized at the genetic and transcriptional level and provide an unique in vitro system for screening the efficacy of both approved drugs and compounds in preclinical development. Furthermore, HUB Organoids can serve as a patient avatar in clinical development and/or diagnostics. More recently, we were able to demonstrate that the in vitro response of HUB Organoids directly correlates with the clinical outcome of the patient from which the organoid was derived (Dekkers et al., Sci Trans Med 2016; Sachs et al., Cell 2018).

Presenter: Dr. Sylvia Boj (CSO HUB)

Date: October 20, 2020

Time: 1:35 PM ET

The NYSCF Conference

November 04, 2020 3 Days of 3D Cell Model Virtual Event 2020 Get ready for 3 days of 3D As organoids, spheroids and the study of 3D cell culture models continue to show their potent... read more
September 04, 2020 HUB and BGI-Qingdao sign a Memorandum of Unde... Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they ... read more
May 27, 2020 Studying the development of ovarian cancer wi... read more